PV
Palvella Therapeutics, Inc.
PVLA · NASDAQ
$152.28 +0.06% (+$0.09)
1M +0.04%
Market Cap $2.23B
P/E Ratio -
Div. Yield -
ROE 47.84%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 10.28x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 23.89%
ROE 47.84%
ROA 24.34%
Debt
69 /100
Low Debt/Equity 0.00x
Current ratio 21.18x
Int. coverage -7.92x
Stability
19 /100
Unstable Beta -0.17x
EPS volatility 154.66%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre PVLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wesley H. Kaupinen
Employees
29
Headquarters
Wayne
Evenimente viitoare
10 NOV.
Earnings
Upcoming earnings report